Ocuphire Pharma Investor Presentation Deck

ZETA-1: Treatment Emergent Adverse Events Oral APX3330 Showed a Favorable Safety and Tolerability Profile Consistent with Prior Trials | Eye disorders | Total AEs Ocuphire PHARMA #of Subjects with AEs Treatment-related AEs Serious AEs Subjects Withdrawals Due to AEs Deaths AES in >5% of Subjects* Diabetic Retinal Edema Diabetic Retinopathy Vitreous detachment Cataract Pruritus Rash COVID-19 Placebo (n=52) 120 35 (67%) 17 (14%) 11 (9%) 1 (2%) 1 (2%) 5 (10%) 6 (12%) 3 (6%) 1 (2%) 1 (2%) 1 (2%) 5 (10%) APX3330 (n=51) 91 29 (57%) 14 (15%) 3 (3%) 2 (4%) 0 (0%) 2 (4%) 1 (2%) 0 (0%) 3 (6%) 6 (12%) 3 (6%) 1 (2%) APX3330 Safety Profile: Limited AEs, most mild in severity ● Pruritis: Mild and resolved without APX3330 dose de-escalation or discontinuation AEs similar to or less than placebo Few serious treatment-related AEs, all unrelated to study medication No ocular AEs other than expected DR progression ● Lower incidence of clinical DR/DME worsening with APX3330 Patients continued routine medications to manage their diabetes comorbidities APX3330 SAES: Dyskinesia, TIA, Chest pain Placebo SAES: Vertigo, Asthenia, Multiple organ dysfunction, Bradycardia, CAD, Cholelithiasis, COVID-19 pneumonia, Cellulitis, Respiratory failure, Skin ulcer, Peripheral embolism AES → Withdrawal APX3330: Presyncope, Dyspnea; Placebo: DME (both eyes) *Preferred Term within Organ Class 28

View entire presentation